Inari MedicalNARI
NARI
About: Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Employees: 1,300
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]
0.25% less ownership
Funds ownership: 93.93% [Q2] → 93.69% (-0.25%) [Q3]
7% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 42
1% less funds holding
Funds holding: 242 [Q2] → 239 (-3) [Q3]
14% less capital invested
Capital invested by funds: $2.63B [Q2] → $2.25B (-$377M) [Q3]
15% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 86
21% less call options, than puts
Call options by funds: $4.53M | Put options by funds: $5.72M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
6%
downside
Avg. target
$66
19%
upside
High target
$75
35%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Truist Securities Richard Newitter 80% 1-year accuracy 40 / 50 met price target | 14%upside $63 | Hold Maintained | 18 Dec 2024 |
Oppenheimer Steve Lichtman 0% 1-year accuracy 0 / 2 met price target | 35%upside $75 | Outperform Initiated | 17 Dec 2024 |
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target | 33%upside $74 | Buy Maintained | 29 Oct 2024 |
Baird David Rescott 79% 1-year accuracy 11 / 14 met price target | 21%upside $67 | Outperform Maintained | 29 Oct 2024 |
Piper Sandler Adam Maeder 63% 1-year accuracy 10 / 16 met price target | 6%downside $52 | Neutral Maintained | 29 Oct 2024 |
Financial journalist opinion
Based on 7 articles about NARI published over the past 30 days
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Inari Medical, Inc. (NARI) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Neutral
Accesswire
6 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Inari Medical, Inc. (NARI) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Neutral
Accesswire
1 week ago
NARI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Inari Medical, Inc. and Encourages Investors to Contact the Firm
NEW YORK CITY, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Positive
Zacks Investment Research
2 weeks ago
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
Positive
Zacks Investment Research
2 weeks ago
NARI Stock Likely to Gain Following Reimbursement Approval in Japan
Inari Medical announces reimbursement approval for ClotTriever Thrombectomy System in Japan and a new distribution partnership with Medikit.
Neutral
GlobeNewsWire
2 weeks ago
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
Reimbursement approval supports expanded access to effective, safe thrombus removal for patients suffering from deep vein thrombosis (DVT) in Japan Reimbursement approval supports expanded access to effective, safe thrombus removal for patients suffering from deep vein thrombosis (DVT) in Japan
Neutral
GlobeNewsWire
2 weeks ago
Inari Medical Announces Joint Venture in Greater China
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced it has entered into a joint venture with 6 Dimensions Capital (“6 Dimensions”) and its successor fund 120 Capital, and VFLO Medical (“VFLO”), a medical device platform incubated by 6 Dimensions and 120 Capital, to provide access to Inari's innovative technology for patients with significant unmet needs in Greater China.
Neutral
GlobeNewsWire
1 month ago
PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism
Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization
Negative
Zacks Investment Research
1 month ago
Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y
NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
Neutral
Seeking Alpha
1 month ago
Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript
Inari Medical, Inc. (NASDAQ:NARI ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Marissa Bych - VP, IR Drew Hykes - President and CEO Kevin Strange - CFO Tom Tu - Chief Medical Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG David Rescott - Baird Chris Pasquale - Nephron Research Stephanie Piazzola - Bank of America Lei Huang - Wells Fargo Zachary Day - Canaccord Genuity Michael Sarcone - Jefferies Ravi Misra - Truist Securities Matthew Blackman - Stifel Operator Good day, and welcome to the Inari Medical Third Quarter 2024 Earnings Call. [Operator Instructions] Also, please be aware that today's call is being recorded.
Charts implemented using Lightweight Charts™